Intermediate-to-high baseline immune infiltration, a higher tumor inflammation signature and higher interferon-γ levels were predictive of the response to flotetuzumab; in contrast, although PD-L1 and markers of CD8+ T-cell exhaustion and senescence-like CD244, EOMES, LAG3 and PTGER4 were overexpressed in the TP53-mutated population, they did not predict the response to flotetuzumab [92]. Here, TP53 is linked to neoplasm.